Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03785184
Registration number
NCT03785184
Ethics application status
Date submitted
20/12/2018
Date registered
24/12/2018
Date last updated
28/08/2019
Titles & IDs
Public title
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
Query!
Scientific title
A Phase 2, Multicenter, Single Arm, Open Label Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
Query!
Secondary ID [1]
0
0
M16-104
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - venetoclax
Treatment: Drugs - lenalidomide
Treatment: Drugs - dexamethasone
Experimental: Venetoclax + Lenalidomide + Dexamethasone - Venetoclax up to 800 mg orally every day (QD) QD on Days 1 - 28 plus lenalidomide up to 25 mg orally QD on Days 1 - 21 (28 day cycle) plus dexamethasone up to 40 mg orally once weekly (QW).
Treatment: Drugs: venetoclax
tablet; oral
Treatment: Drugs: lenalidomide
capsule; oral
Treatment: Drugs: dexamethasone
tablet; oral
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participates Who Achieve CR
Query!
Assessment method [1]
0
0
Complete response (CR) is defined as negative immunofixation of serum and urine, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in bone marrow.
Query!
Timepoint [1]
0
0
From baseline up to approximately 24 months
Query!
Secondary outcome [1]
0
0
Percent of Participants Who Achieve MRD Negativity
Query!
Assessment method [1]
0
0
Minimal residual disease (MRD) negative after treatment is described as less than one myeloma cell per 100,000 bone marrow cells.
Query!
Timepoint [1]
0
0
From baseline up to approximately 24 months
Query!
Secondary outcome [2]
0
0
Percent of Participants Who Achieve VGPR or Better
Query!
Assessment method [2]
0
0
Very Good Partial Response (VGPR) per international myeloma working group (IMWG) criteria is defined as serum or urine myeloma protein (m-protein) detectable by immunofixation but not on electrophoresis, or greater than or equal to 90% reduction in serum m-protein and urine m-protein less than 100 mg/24 hours.
Query!
Timepoint [2]
0
0
From baseline up to approximately 24 months
Query!
Secondary outcome [3]
0
0
Overall Response Rate (ORR)
Query!
Assessment method [3]
0
0
ORR is described as the percentage of participants who experience partial response (PR) or better; PR per IMWG is described as follows:
= 50% reduction of serum M-protein and reduction in 24-hour urinary M protein by = 90% or to < 200 mg/24 h
If the serum and urine M-protein are not measurable, a decrease = 50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria
If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, = 50% reduction in bone marrow plasma cells is required in place of M-protein, provided baseline percentage was = 30%
In addition, if present at baseline, = 50% reduction in size of soft tissue plasmacytomas is also required
Query!
Timepoint [3]
0
0
From baseline up to approximately 24 months
Query!
Secondary outcome [4]
0
0
Time to Response (TTR)
Query!
Assessment method [4]
0
0
Time to response is defined as the time from randomization to the first response (CR, stringent complete response [sCR], VGPR, PR).
Query!
Timepoint [4]
0
0
From baseline up to approximately 24 months
Query!
Secondary outcome [5]
0
0
Duration of response (DOR)
Query!
Assessment method [5]
0
0
DOR is defined as the time from first observation of PR to the time of disease progression, with deaths from causes other than progression censored.
Query!
Timepoint [5]
0
0
Approximately 7 years
Query!
Secondary outcome [6]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [6]
0
0
PFS is defined as time from start of the treatment to disease progression or death (regardless of cause of death), whichever comes first.
Query!
Timepoint [6]
0
0
Approximately 7 years
Query!
Secondary outcome [7]
0
0
Minimal Residual Disease (MRD) Negativity Rate at 12 Months
Query!
Assessment method [7]
0
0
Percent of participants meeting the MRD Negative criteria at 12 months after initial dose; MRD Negative defined as less than one myeloma cell per 100,000 bone marrow cells.
Query!
Timepoint [7]
0
0
Approximately 12 months after initial dose of study drug
Query!
Secondary outcome [8]
0
0
Time to Disease Progression (TTP)
Query!
Assessment method [8]
0
0
TTP is defined as the time from start of treatment to disease progression, with deaths from causes other than progression censored.
Query!
Timepoint [8]
0
0
Approximately 7 years
Query!
Secondary outcome [9]
0
0
Time to Next Treatment (TTNT)
Query!
Assessment method [9]
0
0
The time to next treatment is defined as the time between the date of the first study drug intake and the date of the first next treatment intake after study drug discontinuation.
Query!
Timepoint [9]
0
0
Approximately 7 years
Query!
Secondary outcome [10]
0
0
Overall Survival (OS) Rate
Query!
Assessment method [10]
0
0
OS was defined as the time from the date the participant was randomized to the date of death.
Query!
Timepoint [10]
0
0
Approximately 7 years
Query!
Eligibility
Key inclusion criteria
- Must have documented, confirmed active multiple myeloma (MM) with greater than or
equal to 10% clonal bone marrow plasma cells or biopsy-proven bone or extramedullary
plasmacytoma and any one or more of the following myeloma-defining events:
- Evidence of end organ damage attributed to the underlying plasma cell
proliferative disorder and satisfying at least one of the protocol specified
laboratory criteria for calcium elevation, renal failure, anemia, or lytic bone
lesions; OR
- One or more of the biomarkers of malignancy as described in the protocol.
- Must have MM positive for the t(11;14) translocation, as determined by methods
described in the protocol.
- Must have measurable disease defined by at least one of the following criteria:
- Serum M-protein = 1.0 g/dL (immunoglobulin [Ig]G myeloma) or greater than or
equal to 0.5 g/dL (IgA, IgM, IgD, or IgE myeloma);
- Urine M-protein greater than or equal to 200 mg/24 hours;
- Serum free light chain (FLC) greater than or equal to 10 mg/dL (100 mg/L)
provided serum FLC ratio is abnormal.
- Newly diagnosed and not considered a candidate for high-dose therapy and hematopoietic
stem cell transplantation (HSCT)
- Must have Eastern Cooperative Oncology Group performance status less than or equal to
2.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Has a co-existing condition as specified in the protocol.
- Has history of other active malignancies, including myelodysplastic syndromes (MDS)
within the past 3 years with specific exceptions detailed in the protocol.
- Has been treated with or received any of the following:
- Prior or current systemic therapy or hematopoietic stem cell transplantation
(HSCT) for MM (a short course of treatment with corticosteroids equivalent to
dexamethasone 40 mg/day for a maximum of 4 days is allowed before treatment); use
of systemic strong or moderate inhibitor or inducer of cytochrome P450(CYP)3A
within 7 days before the first dose of study drug.
- Radiation therapy within 2 weeks of dosing
- Plasmapheresis within 4 weeks of dosing
- Immunization with live vaccine within 8 weeks of dosing
- Has a contraindication or inability to comply with antithrombotic prophylaxis.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Withdrawn
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
29/04/2019
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
22/08/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
0
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Westmead Hospital /ID# 210267 - Westmead
Query!
Recruitment hospital [2]
0
0
Flinders Centre for Innovation /ID# 210697 - Bedford Park
Query!
Recruitment hospital [3]
0
0
St. Vincents Hosp Melbourne /ID# 210266 - Fitzroy
Query!
Recruitment hospital [4]
0
0
Austin Hospital /ID# 210268 - Heidelberg
Query!
Recruitment hospital [5]
0
0
Monash Medical Centre /ID# 210269 - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [3]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [4]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [5]
0
0
3168 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Michigan
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
North Carolina
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Pennsylvania
Query!
Country [5]
0
0
Canada
Query!
State/province [5]
0
0
Alberta
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
Ontario
Query!
Country [7]
0
0
Canada
Query!
State/province [7]
0
0
Quebec
Query!
Country [8]
0
0
Spain
Query!
State/province [8]
0
0
Navarra, Comunidad
Query!
Country [9]
0
0
Spain
Query!
State/province [9]
0
0
Barcelona
Query!
Country [10]
0
0
Spain
Query!
State/province [10]
0
0
Madrid
Query!
Country [11]
0
0
Spain
Query!
State/province [11]
0
0
Valencia
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AbbVie
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Genentech, Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Commercial sector/Industry
Query!
Name [2]
0
0
Celgene Corporation
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will evaluate the safety and preliminary efficacy of venetoclax when combined with
lenalidomide and dexamethasone for participants with newly diagnosed, active t(11;14)
positive multiple myeloma (MM).
This study will consist of 2 parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03785184
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
AbbVie Inc.
Query!
Address
0
0
AbbVie
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03785184
Download to PDF